Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 7/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | ESR1 | P03372 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24398653 | 0.97 | MIF (0.59) | MIFHDAC3HDAC1HDAC2HSD17B3 | |
| SCHEMBL26938898 | 0.86 | MIF (0.56) | MIFHDAC3HDAC1HDAC2ESR2 | |
| SCHEMBL2766991 | 0.86 | MIF (0.74) | MIFHDAC3HDAC1HDAC2HSD17B3 | |
| SCHEMBL24398656 | 0.85 | MIF (0.54) | MIFHDAC3HDAC1HDAC2ESR2 | |
| SCHEMBL24398530 | 0.84 | MIF (0.43) | MIFHDAC3HDAC1HDAC2HSD17B3 | |
| SCHEMBL26938906 | 0.83 | ESR1 (0.55) | MIFESR2ESR1 | |
| SCHEMBL29507341 | 0.82 | MIF (0.52) | MIFESR2ESR1 | |
| SCHEMBL24398654 | 0.82 | MIF (0.52) | MIFESR2ESR1 | |
| SCHEMBL26938899 | 0.82 | ESR1 (0.50) | MIFESR2ESR1 | |
| SCHEMBL2765998 | 0.82 | MIF (0.70) | MIFHDAC3HDAC1HDAC2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2022093817-A1 | MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | MIF 1/4885HDAC3 3212/4885HDAC1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.